Biological
RP3
RP3 is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)
Phase Distribution
Ph phase_2
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Terminated(2)
Detailed Status
Terminated1
Active, not recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
terminated133%
active_not_recruiting133%
withdrawn133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_1
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
NCT04735978
terminatedphase_2
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
NCT05733611
withdrawnphase_2
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
NCT05743270
Clinical Trials (3)
Showing 3 of 3 trials
NCT04735978Phase 1
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
NCT05733611Phase 2
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
NCT05743270Phase 2
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3